Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease.

Trial Profile

Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2014

At a glance

  • Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Omeprazole
  • Indications Coronary artery disease; Embolism and thrombosis; NSAID-induced gastric damage; Peripheral arterial disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Feb 2012 Planned end date changed from 1 Oct 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
    • 09 Aug 2010 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 09 Aug 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top